Patanol Related Published Studies
Well-designed clinical trials related to Patanol (Olopatadine)
Effects of single therapeutic doses of promethazine, fexofenadine and olopatadine
on psychomotor function and histamine-induced wheal- and flare-responses: a
randomized double-blind, placebo-controlled study in healthy volunteers. [2012]
Comprehensive report of olopatadine 0.6% nasal spray as treatment for children with seasonal allergic rhinitis. [2011.05]
Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis. [2011.03]
Mometasone furoate nasal spray for moderate-to-severe nasal congestion in
subjects with seasonal allergic rhinitis. [2011]
Olopatadine hydrochloride in children: efficacy and safety for perennial allergic rhinitis. [2010.07]
Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis. [2010.03]
Efficacy of oral olopatadine hydrochloride for the treatment of seasonal allergic
rhinitis: A randomized, double-blind, placebo-controlled study. [2010]
Olopatadine hydrochloride in children: efficacy and safety for perennial allergic
rhinitis. [2010]
Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination
with an intranasal corticosteroid in seasonal allergic rhinitis. [2010]
Safety and efficacy of olopatadine hydrochloride nasal spray 0.6% in pediatric subjects with allergic rhinitis. [2009.11]
Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. [2009.08]
Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 microg in the treatment of seasonal allergic rhinitis. [2009.05]
Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults. [2009.01]
Evaluation of the efficacy and safety of olopatadine and fexofenadine compared with placebo in Japanese cedar pollinosis using an environmental exposure unit. [2009]
Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. [2008.07.08]
Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye. [2008.02]
Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge. [2007.12]
Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCl nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared with vehicle placebo. [2006.05]
Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. [2005.12]
Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar. [2005.11]
Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy. [2005.10]
Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. [2005.09]
A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model. [2005.05]
Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis. [2005.05]
Double-blind, crossover comparison of olopatadine and cetirizine versus placebo: suppressive effects on skin response to histamine iontophoresis. [2005.01]
Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model. [2004.12]
Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance. [2004.09]
Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study. [2004.08]
Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. [2004.08]
Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration. [2004.01]
Comparative study of acute effects of single doses of fexofenadine, olopatadine, d-chlorpheniramine and placebo on psychomotor function in healthy volunteers. [2003.12]
Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. [2003.10]
Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. [2003.08]
Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. [2003.08]
One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tears. [2003.07]
Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model. [2003.04]
A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis. [2003.03]
Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: a real-world comparison of efficacy and ocular comfort. [2003.03]
Rapid effects of olopatadine hydrochloride on the histamine-induced skin responses. [2002.11]
A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. [2002.10]
Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge. [2002.07]
Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model. [2002.06]
Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. [2001.08]
Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms. [2001.06]
Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. [2000.12]
A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model. [2000.07]
A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%. [2000]
An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. [2000]
The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model. [1999]
Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. [1999]
Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. [1998.09]
Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. [1998.06]
Well-designed clinical trials possibly related to Patanol (Olopatadine)
Double dose of cetirizine hydrochloride is effective for patients with urticaria
resistant: a prospective, randomized, non-blinded, comparative clinical study and
assessment of quality of life. [2013]
[Comparison of olopatadin and ketotifen in the treatment of allergic conjunctivitis] [2009.07]
Comparison of a new antihistaminic and antiallergic compound KW 4679 with terfenadine and placebo on skin and nasal provocation in atopic individuals. [1994.10]
Other research related to Patanol (Olopatadine)
Comparative evaluation of olopatadine 0.01% combined fluorometholone 0.1%
treatment versus olopatadine 0.01% combined ketorolac 0.4% treatment in patients
with acute seasonal allergic conjunctivitis. [2014]
Evaluation of the antihistamine effects of olopatadine and levocetirizine during
a 24-h period: a double-blind, randomized, cross-over, placebo-controlled
comparison in skin responses induced by histamine iontophoresis. [2013]
Effect of intranasal fluticasone furoate and intraocular olopatadine on nasal and
ocular allergen-induced symptoms. [2013]
A multicenter, double-blind, randomized, noninferiority comparison of 14 days'
treatment with oral olopatadine 10 mg or cetirizine 10 mg in Chinese adults with
cutaneous pruritus. [2013]
Effects of single therapeutic doses of promethazine, fexofenadine and olopatadine on psychomotor function and histamine-induced wheal- and flare-responses: a randomized double-blind, placebo-controlled study in healthy volunteers. [2011.12.01]
Olopatadine hydrochloride and rupatadine fumarate in seasonal allergic rhinitis: A comparative study of efficacy and safety. [2011.10]
Pre-seasonal treatment with topical olopatadine suppresses the clinical symptoms of seasonal allergic conjunctivitis. [2011.04]
Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis. [2011.02.08]
Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%. [2011.01.13]
Olopatadine hydrochloride inhibits capsaicin-induced flare response in humans. [2011]
Efficacy of oral olopatadine hydrochloride for the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled study. [2010.07]
Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis. [2010.07]
Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older. [2010.06]
Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. [2010.04]
Comprehensive review of olopatadine: the molecule and its clinical entities. [2010.03]
Olopatadine nasal spray for the treatment of allergic rhinitis. [2010.03]
Synergetic effects of prednisolone and olopatadine on atopic dermatitis model of hairless mice. [2010]
Olopatadine hydrochloride improves dermatitis score and inhibits scratch behavior in NC/Nga mice. [2010]
Comparison of olopatadine and fluorometholone in contact lens-induced papillary
conjunctivitis. [2010]
Azelastine and olopatadine in the treatment of allergic rhinitis. [2009.11]
Severity scores, itch scores and plasma substance P levels in atopic dermatitis treated with standard topical therapy with oral olopatadine hydrochloride. [2009.04]
Efficacy of repeated pretreatment with olopatadine hydrochloride on rhinitis induced by intranasal instillation of toluene-2,4-diisocyanate in rats. [2009]
[Effectiveness of olopatadine therapy in seasonal allergic conjunctivitis] [2009]
Use of olopatadine ophthalmic solution and reactivity of histamine skin testing. [2008.11]
Comparative study of sensory attributes of two antihistamine nasal sprays: Olopatadine 0.6% and azelastine 0.1%. [2008.11]
A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis. [2008.11]
Effects of olopatadine in limited scleroderma with peripheral eosinophils. [2008.09]
The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation. [2008.07]
Evaluation of the antihistamine effects of olopatadine, cetirizine and fexofenadine during a 24 h period: a double-blind, randomized, crossover, placebo-controlled comparison in skin responses induced by histamine iontophoresis. [2008.07]
Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing. [2008.04]
Evaluation of the antihistamine effects of olopatadine, cetirizine and fexofenadine during a 24 h period: a double-blind, randomized, crossover, placebo-controlled comparison in skin responses induced by histamine iontophoresis. [2008.02.28]
Olopatadine ameliorates rat experimental cutaneous inflammation by improving skin barrier function. [2008]
The noncompetitive antagonism of histamine H1 receptors expressed in Chinese hamster ovary cells by olopatadine hydrochloride: its potency and molecular mechanism. [2008]
An assessment of the onset and duration of action of olopatadine nasal spray. [2007.12]
Perception and Quality of Life Associated With the Use of Olopatadine 0.2% (Patadaytrade mark) in Patients With Active Allergic Conjunctivitis. [2007.11]
Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6% and Olopatadine 0.4% treatment in patients with seasonal allergic rhinitis. [2007.11]
Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis. [2007.11]
Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate. [2007.09]
Safety and tolerability of olopatadine 0.2% in children and adolescents. [2007.08]
Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis. [2007.07]
The effect of H1 antagonists carebastine and olopatadine on histamine induced expression of CC chemokines in cultured human nasal epithelial cells. [2007.06]
Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. [2007.06]
Olopatadine hydrochloride accelerates the recovery of skin barrier function in mice. [2007.05]
Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca. [2007.02]
Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. [2006.12]
Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study. [2006.10]
|
